Credit Suisse Reiterates Neutral, Raises PT On Pharmacyclics As Deal Looks Likely To Happen

By: via Benzinga
In a report published Friday, Credit Suisse analyst Jason Kantor reiterated a Neutral rating on Pharmacyclics, Inc. (NASDAQ: PCYC), and ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.